Navigation Links
Arteriocyte Receives $1 Million Award From Ohio Third Frontier Program to Advance Its NANEX™ Technology Toward Clinical Use
Date:7/20/2011

CLEVELAND, July 20, 2011 /PRNewswire/ -- Arteriocyte®, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies announced today that the Ohio Department of Development's Third Frontier Commission awarded a $1 million grant to the company for its "Development and Commercialization of Hematopoietic Stem Cell Expansion for Clinical Applications" as part of the Ohio Third Frontier Biomedical Program to accelerate the company's Good Manufacturing Practices (GMP) manufacturing of its NANEX™ technology for clinical use under the product name HemaEx.

(Logo: http://photos.prnewswire.com/prnh/20100624/ALOGO)

The NANEX™ technology is a biofunctional nanofiber-based 3D scaffold designed to mimic the bone marrow environment, permitting rapid ex vivo proliferation of hematopoietic stem cells with minimal differentiation. This technology was licensed from John Hopkins University to enhance proprietary stem cell therapies targeting cardiovascular disease and cancer. Arteriocyte launched the technology commercially as a research-use "NANEX™ Hematopoietic stem cell expansion kit" in December 2010. This kit, combining NANEX™ culture ware with proprietary culture medium and growth factors, enables scientists to rapidly expand HSCs for their preclinical research.

Arteriocyte will deploy the current funding to rapidly scale its Cleveland-based NANEX™ production facility to manufacture GMP-compliant, "clinic-ready" HemaEx culture ware. The company anticipates working closely with clinical partners at the Ohio State University to validate use of the HemaEx system during treatment of blood born cancers. Additionally, this award will enable Arteriocyte to expand its strategic partnership with Miltenyi Biotec to include GMP-grade media additives that are safe for human use. The company anticipates launch of its first GMP NANEX™ product for clinical research use within the next year, followed closely by regulatory submittal to allow clinical cell therapy production by 2013.

"The Third Frontier Program is eager to invest in innovative technologies like Arteriocyte's that advance the biomedical industry in the state," said Norm Chagnon, Executive Director for the Ohio Third Frontier for the Ohio Third Frontier. "The company has a proven track record of developing world-class technologies and growing the talent-base in the region, while creating jobs and revenue for the State of Ohio."

Arteriocyte CEO Don Brown said, "Ohio's Third Frontier Program has been one of Arteriocyte's earliest and most consistent investment partners. Their support has been a driving force contributing to the growth of our company and rapid development of these novel technologies. Today's award will enable Arteriocyte to advance our NANEX™ products forward to clinically relevant cellular therapy products here in Northeast Ohio."

About Arteriocyte

Arteriocyte, a leading clinical stage biotechnology company, is dedicated in developing novel stem cell products and medical devices for unmet clinical needs. Arteriocyte leverages its expertise in stem cell and tissue engineering in order to develop a broad portfolio of cell based therapeutics to improve patient outcomes. In October of 2007, Arteriocyte partnered with DW Healthcare Partners and Comerica to create Arteriocyte Medical Systems Inc., in order to commercialize and distribute novel medical devices and point of care surgical solutions to address serious unmet medical needs in cardiac, orthopedic and vascular surgeries. Arteriocyte Medical Systems manufactures and distributes the Magellan® Autologous Platelet Separator System.


'/>"/>
SOURCE Arteriocyte
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma
2. Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial
3. Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010
4. Metabolic Solutions Development Company Receives $773,000 From the Alzheimers Drug Discovery Foundation to Fund Phase 2a Trial
5. Unity Management Group, MCC Receives Authorization for Second Purchase Order From Bristol Meyers Squibb
6. TALEN® Access by Cellectis Bioresearch Receives "Most Innovative New Service 2011" Award at Life Science Awards
7. Sorrento Therapeutics Innovative Approach to Developing Vaccines and Therapeutics for MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases
8. Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
9. China-Biotics, Inc. Receives NASDAQ Delisting Notification
10. UCSB professor receives Presidential Green Chemistry Challenge Award
11. Genesis Biosciences Receives Pulire Innovation Award for e card Sanitary Bin Treatment Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... focused on quality, regulatory and technical consulting, provides a free webinar ... presented on July 13, 2016 at 12pm CT at no charge. , Incomplete ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... partnership that will allow them to produce up ... (HiPSC) from one lot within one week. These ... their time laboriously preparing cells and spend more ... made possible through a proprietary, high-volume manufacturing process ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):